Shah, N. P., Kim, D., Kantarjian, H., Rousselot, P., Llacer, P. E. D., Enrico, A., . . . Hochhaus, A. (2010). Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Ferrata Storti Foundation.
Παραπομπή Chicago StyleShah, Neil P., et al. Potent, Transient Inhibition of BCR-ABL With Dasatinib 100 Mg Daily Achieves Rapid and Durable Cytogenetic Responses and High Transformation-free Survival Rates in Chronic Phase Chronic Myeloid Leukemia Patients With Resistance, Suboptimal Response or Intolerance to Imatinib. Ferrata Storti Foundation, 2010.
Παραπομπή MLAShah, Neil P., et al. Potent, Transient Inhibition of BCR-ABL With Dasatinib 100 Mg Daily Achieves Rapid and Durable Cytogenetic Responses and High Transformation-free Survival Rates in Chronic Phase Chronic Myeloid Leukemia Patients With Resistance, Suboptimal Response or Intolerance to Imatinib. Ferrata Storti Foundation, 2010.